Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: A combination therapy study with tissue plasminogen activator

Brain Research

Volumn 1309, Issue , 2010, Pages 136-145

  Lapchak, Paul A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute ischemic stroke; Behavior; Clinical; Embolism; Intracerebral hemorrhage; Neuroprotection; Toxicity; Translational science

Indexed keywords

CAROTENOID; SODIUM CHLORIDE; TISSUE PLASMINOGEN ACTIVATOR; TRANS SODIUM CROCETINATE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; MALE; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; TREATMENT RESPONSE;

ANIMALS; BRAIN INFARCTION; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUG TOXICITY; EMERGENCY MEDICAL SERVICES; FIBRINOLYTIC AGENTS; INTRACRANIAL EMBOLISM; MALE; NEUROPROTECTIVE AGENTS; RABBITS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VITAMIN A;

ORYCTOLAGUS CUNICULUS;

EID: 72049086023     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.10.067     Document Type: Article

References (64)

1. Abe K., and Saito H. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. Phytother. Res. 14 (2000) 149-152
2. Albers G.W., Bates V.E., Clark W.M., Bell R., Verro P., and Hamilton S.A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150
3. Belayev L., Becker D.A., Alonso O.F., Liu Y., Busto R., Ley J.J., and Ginsberg M.D. Stilbazulenyl nitrone, a novel azulenyl nitrone antioxidant: improved neurological deficit and reduced contusion size after traumatic brain injury in rats. J. Neurosurg. 96 (2002) 1077-1083
4. Broderick J.P., Lu M., Kothari R., Levine S.R., Lyden P.D., Haley E.C., Brott T.G., Grotta J., Tilley B.C., Marler J.R., and Frankel M. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 31 (2000) 2335-2341
5. Clark W.M., Albers G.W., Madden K.P., and Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 31 (2000) 811-816
6. Del Zoppo G.J., Saver J.L., Jauch E.C., and Adams Jr. H.P. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke 40 8 (2009) 2945-2948
7. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
8. dos Santos M.D., Almeida M.C., Lopes N.P., and de Souza G.E. Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. Biol. Pharm. Bull. 29 (2006) 2236-2240
9. EAISG. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 15 (2003) 222-229
10. Floyd R.A. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222 (1999) 236-245
11. Gainer J.L. Trans-sodium crocetinate for treating hypoxia/ischemia. Expert Opin. Investig. Drugs 17 (2008) 917-924
12. Giaccio M. Crocetin from saffron: an active component of an ancient spice. Crit. Rev. Food Sci. Nutr. 44 (2004) 155-172
13. Giassi L.J., Gilchrist M.J., Graham M.C., and Gainer J.L. Trans-sodium crocetinate restores blood pressure, heart rate, and plasma lactate after hemorrhagic shock. J. Trauma 51 (2001) 932-938
14. Giassi L.J., Poynter A.K., and Gainer J.L. Trans sodium crocetinate for hemorrhagic shock: effect of time delay in initiating therapy. Shock 18 (2002) 585-588
15. NINDS rt-PA Trial. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333 (1995) 1581-1587
16. Higashi Y., Jitsuiki D., Chayama K., and Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents Cardiovasc. Drug. Discov. 1 (2006) 85-93
17. Ingall T. Stroke-incidence, mortality, morbidity and risk. J. Insur. Med. 36 (2004) 143-152
18. Kitagawa Y. Edaravone in acute ischemic stroke. Intern. Med. 45 (2006) 225-226
19. Lampl Y., Zivin J.A., Fisher M., Lew R., Welin L., Dahlof B., Borenstein P., Andersson B., Perez J., Caparo C., Ilic S., and Oron U. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke 38 (2007) 1843-1849
20. Lansberg M.G., Schrooten M., Bluhmki E., Thijs V.N., and Saver J.L. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke 40 (2009) 2079-2084
21. Lapchak P.A. Development of thrombolytic therapy for stroke: a perspective. Expert Opin. Investig. Drugs 11 (2002) 1623-1632
22. Lapchak P.A. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr. Neurol. Neurosci. Rep. 2 (2002) 38-43
23. Lapchak P.A. 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. Exp. Neurol. 197 (2006) 531-537
24. Lapchak P.A. The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator. Exp. Neurol. 205 (2007) 407-413
25. Lapchak P.A. Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model. Brain Res. 1294 (2009) 211-217
26. Lapchak P.A., and Zivin J.A. Ebselen, a seleno-organic antioxidant, is neuroprotective after emoblic strokes in rabbits-synergism with low dose tissue plasminogen activator. Stroke 34 (2003) 2013-2018
27. Lapchak P.A., and Araujo D.M. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin. Emerg. Drugs 12 (2007) 97-112
28. Lapchak P.A., and Araujo D.M. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin. Emerg. Drugs 12 (2007) 389-406
29. Lapchak P.A., and Han M.K. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Res. 1303 (2009) 144-150
30. Lapchak P.A., and Zivin J.A. The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp. Neurol. 215 (2009) 95-100
31. Lapchak P.A., Araujo D.M., Song D., Wei J., and Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33 (2002) 1411-1415
32. Lapchak P.A., Araujo D.M., and Zivin J.A. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp. Neurol. 185 (2004) 154-159
33. Lapchak P.A., Song D., Wei J., and Zivin J.A. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp. Neurol. 188 (2004) 279-285
34. Lapchak P.A., Song D., Wei J., and Zivin J.A. Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence. Exp. Neurol. 188 (2004) 286-291
35. Lapchak P.A., Wei J., and Zivin J.A. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke 35 (2004) 1985-1988
36. Lapchak P.A., Maher P., Schubert D., and Zivin J.A. Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 150 (2007) 585-591
37. Lapchak P.A., Salgado K.F., Chao C.H., and Zivin J.A. Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes. Neuroscience 148 (2007) 907-914
38. Lapchak P.A., Han M.K., Salgado K.F., Streeter J., and Zivin J.A. Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits. Stroke 39 (2008) 3073-3078
39. Lyden P.D., and Zivin J.A. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc. Brain Metab. Rev. 5 (1993) 1-16
40. Lyden P.D., Zivin J.A., Soll M., Sitzer M., Rothrock J.F., and Alksne J. Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. Arch. Neurol. 44 (1987) 848-850
41. Lyden P.D., Madden K.P., Clark W.M., Sasse K.C., and Zivin J.A. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke 21 (1990) 1589-1593
42. Lyden P.D., Jackson-Friedman C., Shin C., and Hassid S. Synergistic combinatorial stroke therapy: a quantal bioassay of a GABA agonist and a glutamate antagonist. Exp. Neurol. 163 (2000) 477-489
43. Maher P., Salgado K.F., Zivin J.A., and Lapchak P.A. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res. 1173 (2007) 117-125
44. Manabe H., Y. R., and Okonkwo D.O. Trans-sodium crocetinate (TSC) limits ischemic brain injury. Soc. Neurosci. (2007)
45. Masella R., Di Benedetto R., Vari R., Filesi C., and Giovannini C. Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes. J. Nutr. Biochem. 16 (2005) 577-586
46. Nijveldt R.J., van Nood E., van Hoorn D.E., Boelens P.G., van Norren K., and van Leeuwen P.A. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74 (2001) 418-425
47. Okonkwo D.O., Wagner J., Melon D.E., Alden T., Stone J.R., Helm G.A., and Jane Sr. J.A. Trans-sodium crocetinate increases oxygen delivery to brain parenchyma in rats on oxygen supplementation. Neurosci. Lett. 352 (2003) 97-100
48. Roy J.W., Graham M.C., Griffin A.M., and Gainer J.L. A novel fluid resuscitation therapy for hemorrhagic shock. Shock 10 (1998) 213-217
49. Saver J.L., Gornbein J., Grotta J., Liebeskind D., Lutsep H., Schwamm L., Scott P., and Starkman S. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window. Joint Outcome Table Analysis of the ECASS 3 Trial. Stroke 40 7 (2009) 2433-2437
50. Seyde W.C., McKernan D.J., Laudeman T., Gainer J.L., and Longnecker D.E. Carotenoid compound crocetin improves cerebral oxygenation in hemorrhaged rats. J. Cereb. Blood Flow Metab. 6 (1986) 703-707
51. Sheehan J., Sherman J., Cifarelli C., Jagannathan J., Dassoulas K., Olson C., Rainey J., and Han S. Effect of trans sodium crocetinate on brain tumor oxgenation. J. Neurosurg. 111 2 (2009) 226-229
52. Stennett A.K., and Gainer J.L. TSC for hemorrhagic shock: effects on cytokines and blood pressure. Shock 22 (2004) 569-574
53. Stennett A.K., Dempsey G.L., and Gainer J.L. trans-Sodium crocetinate and diffusion enhancement. J. Phys. Chem., B 110 (2006) 18078-18080
54. Stennett A.K., Murray R.J., Roy J.W., and Gainer J.L. Trans-sodium crocetinate and hemorrhagic shock. Shock 28 (2007) 339-344
55. Stern S.A., Z. B., and Want X. The effects of resuscitation with trans-sodium crocetinate in a model of hemorrhagic shock and traumatic brain injury. Acad. Emerg. Med. 9 (2002) 415-416
56. Suda S., Igarashi H., Arai Y., Andou J., Chishiki T., and Katayama Y. Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging. Neurol. Med. Chir. (Tokyo) 47 (2007) 197-201 discussion 201-2
57. Tanahashi N., and Fukuuchi Y. Treatment of acute ischemic stroke: recent progress. Intern. Med. 41 (2002) 337-344
58. Watanabe T., Tahara M., and Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc. Ther. 26 (2008) 101-114
59. Waud D.R. On biological assays involving quantal responses. J. Pharmacol. Exp. Theory 183 (1972) 577-607
60. Woodman O.L., and Chan E. Vascular and anti-oxidant actions of flavonols and flavones. Clin. Exp. Pharmacol. Physiol. 31 (2004) 786-790
61. Yamaguchi T., Sano K., Takakura K., Saito I., Shinohara Y., Asano T., and Yasuhara H. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29 (1998) 12-17
62. Yen W.J., Wang B.S., Chang L.W., and Duh P.D. Antioxidant properties of roasted coffee residues. J. Agric. Food Chem. 53 (2005) 2658-2663
63. Zivin J.A., and Waud D.R. Quantal bioassay and stroke. Stroke 23 (1992) 767-773
64. Zivin J.A., Albers G.W., Bornstein N., Chippendale T., Dahlof B., Devlin T., Fisher M., Hacke W., Holt W., Ilic S., Kasner S., Lew R., Nash M., Perez J., Rymer M., Schellinger P., Schneider D., Schwab S., Veltkamp R., Walker M., and Streeter J. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 40 (2009) 1359-1364